Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Wales’ New Treatments Fund

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

- PMLiVE

Another NICE rejection for Roche’s Avastin

Second draft guidance turns down drug’s use in advanced ovarian cancer

- PMLiVE

NICE will take central role in UK’s value-based pricing system

DH confirms role of cost-effectiveness watchdog in drug reimbursement plans from 2014

- PMLiVE

Dismay as NICE turns down Afinitor for breast cancer

Patient groups say draft guidance is a major blow to women in England and Wales

- PMLiVE

GW Pharma says German Sativex pricing “unacceptable”

May pull MS drug from market

- PMLiVE

Is the new NHS guidance relevant to pharma?

The new NHS Commissioning Board has published its most important document of the year - one that will have a huge impact on the industry in 2013

NHS hopes to narrow the digital divide in health

Will provide funding for new 'digital health hubs'

- PMLiVE

NHS launches health app library

Will feature smartphone apps reviewed for clinical safety by the UK health service

NHS London PR spend criticised

But Trusts argue PR is need to educate public

- PMLiVE

The future of market access through a communications lens

Communications will play a pivotal role in helping pharma to define the value agenda

- PMLiVE

UK doctors get online patient access guidance

RCGP looks at practicalities of giving patients online access to records and services

- PMLiVE

Discount convinces NICE to uphold recommendation for Novartis’ Xolair

Asthma drug now also available for children

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links